TATVA1,655.00

Tatva Chintan Pharma Chem Limited

· Chemicals
₹ CrorePeersVISHNUJUBLCPLKIRIINDUSFOSECOINDCHEMPLASTSDDEVPLSTIKGUJALKALIYASHOMcap ₹3,871 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation25.627.736.8
+ Finance Costs6.51.32.9
+ Interest Income-3.3-0.5-0.7
+ Fair Value (Gains) / Losses-0.20.00.0
+ Unrealised FX (Gain) / Loss-0.4-0.02.0
+ Other Non-cash Items0.30.93.1
+ Other — Cash Effects are Investing / Financing-0.0-0.1-0.0
Changes in Working Capital
+ Inventories9.718.8-62.1
+ Trade Receivables — Current15.4-15.2-21.5
+ Other Financial Assets — Current2.2-0.10.6
+ Other Financial Assets — Non-current-1.6-0.0-0.3
+ Other Current Assets-2.1-6.2-3.5
+ Other Non-current Assets-0.3-0.3-0.2
+ Trade Payables — Current11.2-13.119.7
+ Other Financial Liabilities — Current-0.30.0-0.3
+ Other Current Liabilities1.28.14.4
+ Other Non-current Liabilities0.00.00.0
+ Provisions — Current0.00.10.1
+ Provisions — Non-current0.20.11.2
Cash from Operating Activities
Profit Before Tax (per I/S)43.67.657.069.0
+ Total Adjustments (incl. Working Capital)64.321.6-17.8
Cash from Operations (pre-tax)107.929.239.2
+ Income Taxes Paid9.94.57.7
Cash from Operating Activities98.024.731.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)128.576.3113.8
+ Disp of Fixed Assets0.20.10.4
+ Government Grants Received0.00.01.4
+ Interest Received — Investing3.30.50.8
+ Other Inflows / (Outflows) — Investing4.510.4-4.7
Cash from Investing Activities-120.5-65.3-115.8
Cash from Financing Activities
+ Proceeds from Issue of Shares196.60.00.0
+ Proceeds from Borrowings-146.225.784.6
+ Repayment of Borrowings8.63.20.6
+ Interest Paid6.51.32.7
+ Dividends Paid4.74.72.3
+ Other Inflows / (Outflows) — Financing-0.10.0-0.0
Cash from Financing Activities30.516.678.9
Net Changes in Cash (pre-FX)8.0-24.0-5.4
+ Effect of FX Rate Changes on Cash-0.10.1-0.2
Net Changes in Cash7.9-23.9-5.6
Closing Cash35.3
Reference Items
EBITDA68.234.293.2108.1
EBITDA Margin %17.338.9418.4219.45
Free Cash Flow (CFO − Capex)-30.5-51.6-82.3-82.3
Free Cash Flow to Equity-30.8-1.0
Free Cash Flow per Basic Share-13.03-22.06-35.18-35.18
Cash Flow to Net Income3.234.320.75
Cash Paid for Taxes9.94.57.7
Cash Paid for Interest6.51.32.7
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.